GSK revises fiscal 2023 outlook following robust Q3 performance

GSK Plc, the British pharmaceutical giant, has revised its fiscal 2023 earnings and sales outlook upwards following a profitable Q3 on a continuing operations basis, according to CEO Emma Walmsley. The upward revision is primarily attributed to the US introduction of Arexvy, the first RSV vaccine globally. Despite a decline in total profit for the period due to the absence of last year’s gain from Consumer Healthcare’s demerger, GSK now anticipates an increase in adjusted earnings per share between 17-20 percent, adjusted operating profit growth between 13-15 percent, and a turnover increase between 12-13 percent.

On Wednesday, GSK’s share price experienced a brief surge before dropping by 1.4% after its Q3 earnings release. Sales for the quarter increased by 10%, or 16% when excluding COVID-19’s impact. The vaccine segment saw a rise of 33-34%, with Shingrix and Arexvy earning £0.8 billion and £0.7 billion respectively. However, General Medicines sales declined by 2% due to generic competition on older products, despite Trelegy’s 23% growth.

The third quarter also witnessed robust growth in operating profit and continuing EPS throughout the quarter and year to date, driven by reduced charges related to contingent consideration liabilities. Adjusted operating profit and EPS grew by 15% and 17% respectively, owing to effective execution, resilient growth, and higher royalty income. Nevertheless, these gains were slightly offset by increased R&D investments, new product launches, and a 7% reduction in operating profit from lower COVID-19 solution sales.

The company’s Q3 results reflect strong execution and resilient growth counterbalanced by increased investments in R&D and new product launches. Vaccine sales increased by 30 percent year-over-year, while Specialty Medicines sales fell by 6 percent and General Medicines sales dropped by 10 percent. Arexvy sales are projected to reach between £0.9 billion to £1 billion.

Walmsley also highlighted the progress in GSK’s vaccines pipeline, the development of their ultra long-acting HIV portfolio, and significant new prospects in respiratory. Notable Q3 achievements included Arexvy’s approval in Japan as the first RSV vaccine for older adults, supported by promising Phase III trial data. Shingrix demonstrated a perfect efficacy rate in preventing shingles among Chinese adults aged 50 and above, leading to a co-promotion partnership with Zhifei set to begin in 2024. Apretude, a long-acting HIV prevention treatment, received EU approval.

InvestingPro Insights

In light of the recent developments at GSK, InvestingPro offers some valuable insights. According to InvestingPro, GSK yields a high return on invested capital and operates with a high return on assets. These InvestingPro Tips suggest a strong financial performance for the company.

InvestingPro’s real-time data further supports this assessment. GSK holds a market capitalization of $69.15 billion and operates with a P/E ratio of 3.73. The company’s revenue over the last twelve months as of Q2 2023 stands at $37,252.84 million, marking a growth of 5.43%.

Moreover, GSK has maintained its dividend payments for 23 consecutive years, which may be of interest to income-focused investors. For a more comprehensive understanding of the company’s financial health and potential investment opportunities, InvestingPro offers an extensive list of additional tips and data metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.